Application

MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS

Patent Number WO-2024056775-A1

Publication Year 2024

Application Year 2023

Priority Year 2022

Jurisdiction WO

Status N/A

Inventors

JENSEN THOMAS ANDERSEN THOMAS JESSING MIKKEL NIELSEN JACOB DAVER HENRIK JONES CHRISTOPHER RICHARD

Applicants

  1. Lundbeck (Denmark)

    2. [NORA names: Lundbeck; Private Research; Denmark; Europe, EU; Nordic; OECD]

  2. Ligand Pharmaceuticals (United Kingdom)

    3. [NORA names: United Kingdom; Europe, Non-EU; OECD]

Abstract

The present invention is directed to compounds of formula IIa. These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.

Patent Family Records (2)

MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)

2024, WO-2024056775-A1

Leucine-rich repeat kinase 2 (LRRK2) inhibitors  

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)

2024, US-11958865-B1

Data Provider: Digital Science

LINKS
-

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+